These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7111953)

  • 21. Effect of Ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia.
    Simpson IA; Lorimer AR; Walker ID; Davidson JF
    Thromb Haemost; 1985 Aug; 54(2):442-4. PubMed ID: 4082082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of various types of hyperlipoproteinaemia with a combination of Mg-chlorophenoxy-isobutyrate and mesoinositol-hexanicotinate (author's transl)].
    Bolzano K; Krempler F; Haslauer F
    Arzneimittelforschung; 1979; 29(10):1621-4. PubMed ID: 583231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacology and mechanism of action of etofibrate].
    Schatton W
    Med Welt; 1982 Sep; 33(38):1310-4. PubMed ID: 6752630
    [No Abstract]   [Full Text] [Related]  

  • 24. [Current treatment with clofibrate or clofibric acid (Regadrin)].
    Reuter W
    Z Arztl Fortbild (Jena); 1982 May; 76(10):437-41. PubMed ID: 7136026
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical experience with bezafibrate.
    Schubotz R; Schneider J; Hausmann L; Mühlfellner G; Mühlfellner O; Kaffarnik H
    Artery; 1980; 8(6):553-9. PubMed ID: 7259534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plafibride: clinical trial of a new platelet antiaggregating agent.
    Olivella J; Vicens B
    Arzneimittelforschung; 1981; 31(10a):1856-8. PubMed ID: 7032532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia.
    Dick TB; Marples J; Ledermann HM; Whittington J
    Curr Med Res Opin; 1981; 7(8):489-502. PubMed ID: 7030635
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical trials of plafibride in geriatric patients.
    Demichelis Genesio MA; Bracons R; Vicens B; Zapatero J; Bruseghini L
    Arzneimittelforschung; 1981; 31(10a):1852-5. PubMed ID: 7198465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ciprofibrate in the treatment of combined hyperlipoproteinemia. Results in more than 600 patients from 23 centers in the Czech Republic].
    Ceska R; Kvasnicka T; Haas T; Soska V; Vaverková H
    Vnitr Lek; 2000 Mar; 46(3):157-60. PubMed ID: 11048518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double-blind study on the activity of plafibride in the treatment of type IV hyperlipoproteinemia.
    Ferreira IJ; del Rio A; González-Viejo N; Vicens B
    Arzneimittelforschung; 1981; 31(10a):1859-62. PubMed ID: 7032533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P; Weisweiler P
    Artery; 1980; 7(6):464-70. PubMed ID: 7236016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [On the effect of etofylline clofibrate on serum lipids and lipoproteins in patients with hyperlipoproteinemia of various degrees (author's transl)].
    Schneider J; Mühlfellner G; Mühlfellner O; Hausmann L; Schubotz R
    Arzneimittelforschung; 1980; 30(11b):2059-62. PubMed ID: 7194060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of combination therapy of clofibric acid and nicotinic acid derivatives on fatty acid metabolism in hyperlipoproteinemia].
    Reuter W
    Z Gesamte Inn Med; 1982 Oct; 37(20):682-8. PubMed ID: 6818779
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations].
    Füsgen I; Summa JD
    Med Klin; 1980 Nov; 75(23):823-5. PubMed ID: 7442597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
    Altomonte L; Mingrone G; Negrini A; De Cunto F; Greco AV
    Clin Ter; 1981 Jan; 96(1):31-8. PubMed ID: 7016409
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical evaluation of pirozadil, administered continuously over four and a half years, in patients with hyperlipoproteinemia type IIa].
    Cuchi de la Cuesta C; Cuchi Alfaro MT; Cuchi Alfaro C
    Rev Clin Esp; 1989 Jan; 184(1):24-6. PubMed ID: 2704867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bezafibrate in primary hyperlipidemias (author's transl)].
    Wechsler JG; Hutt V; Klör HU; Bode G; Ditschuneit H
    Klin Wochenschr; 1982 Jan; 60(2):97-105. PubMed ID: 7070008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
    Naruszewicz M; Nowicka G; Szostak WB; Kłosiewicz-Latoszek L
    Kardiol Pol; 1982; 25(7-8):527-31. PubMed ID: 7169740
    [No Abstract]   [Full Text] [Related]  

  • 39. [Plafibride--is it an effective drug as a hypolipemic agent?].
    Joven J
    Med Clin (Barc); 1985 Apr; 84(15):632. PubMed ID: 3999857
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical trial of a new drug for the treatment of atherosclerosis: pirozadil (722-D) (author's transl)].
    Marín Plaza R; Díaz González JM; Varela de Seijas JR
    Med Clin (Barc); 1982 May; 78(10):427-32. PubMed ID: 7047924
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.